Wockhardt exits its US generics business

Wockhardt Ltd comes out of the US generic work because new antibiotics focus on drug discovery and insulin portfolios.

Drug producer said on Friday, US subsidiary Morton Grove Pharmaceuticals Inc. and Wockhardt said USA LLC was doing the Part 7 Files for the voluntary liquidation. The job has been damaged in the last few years and a loss of about $ 8 million in 25 financial years.

In an interview with MINT in April, Wockhardt President Habil Khorakiwala said the company plans to leave the US generic segment for its “organization basically leather”. The company will continue to carry out pharmaceutical operations in India, England, Ireland and other geographies.

Focus on antibiotics

The US market has become “very uncertain ,, in an interview with Khorakiwala, the company’s focus will be to improve the antibiotic pipeline for the global market, and that the generic pharmaceutical business will focus on the rest of its current markets. “It will increase profits because we’re losing money in the US,” he said.

Wockhardt focuses on a new antibiotic pipeline for drug -resistant bacterial infections and new biobenzer drugs for diabetes treatment and new drug discovery program.

It has six new antibiotic pipe lines targeting bacterial drug resistance. Two of them, Emrok and Miqnaf, have already been released in India. The third drug candidate Zaynich completed his global phase 3 trials with promising results. Wockhardt applied for approval with the Indian drug regulator and is waiting for approval in the second half of the 26 financial years. At an investor meeting in June, 27 said that with a potential launch, the US FDA was planning to file with FDA in FY26.

Zaynich can potentially change the corporation of the company with a two million addressable patient pool. The company said that the addressable market potential for Zaynich is $ 7 billion in the US and Europe.

Wockhardt is also trying to build insulin more firmly for India and developing markets. The company doubles its capacity in the next three years to meet the increasing demand in the field.